Today’s executive order that cannabis will be rescheduled from Schedule I to Schedule III under the Controlled Substances Act marks a significant shift in federal drug policy. The change does not amount amount to an act of Congress. Nor does this amount to full federal legalization. However, it reflects a formal recognition that cannabis has accepted medical use under federal law. This means marijuana no longer belongs in the most restrictive category of controlled substances.
For cannabis businesses, one of the most immediate legal questions raised by this development is how this announcement affects intellectual property rights. In particular is the potential availability of federal trademark protection.
Why Cannabis Has Always Been Patentable
Cannabis-related inventions have long been eligible for patent protection in the United States. Patent law does not require an inventor to show that an invention is legal to sell or use. Instead, the patent system asks a different question. Is the invention new, useful, nonobvious, and properly disclosed?
Because of that distinction, the USPTO has issued cannabis-related patents for decades. These include patents covering cannabis plants, extraction and processing methods, formulations, delivery devices, and cultivation technology. Federal illegality has never barred the issuance of these patents.
This reality often confuses cannabis businesses. Many assume that if an invention can be patented, the associated brand should also qualify for trademark protection. That assumption is understandable, but incorrect. Trademark law requires lawful use in commerce. Patent law does not. Each system applies its own legal test, and federal illegality affects them in very different ways.
Why Federal Trademarks Have Historically Been Unavailable
Under U.S. trademark law, a mark must be used in lawful commerce to qualify for federal registration. For decades, cannabis businesses have been unable to meet this requirement because of marijuana’s classification as a Schedule I controlled substance. This scheduling rendered its manufacture, sale, and distribution unlawful under federal law, regardless of permissive state statutes.
This legal barrier has existed independently of enforcement discretion. Even during periods when federal authorities deprioritized marijuana enforcement, the underlying statutory illegality remained unchanged. As a result, the United States Patent and Trademark Office has consistently refused to register trademarks for cannabis goods and services.
Federal Supremacy and the Limits of State Legalization
Any discussion of cannabis regulation starts and ends with the Supreme Court’s decision in Gonzales v. Raich (2005). In that case, the Court held that Congress has authority under the Commerce Clause to prohibit local cultivation and use of marijuana. Federal prohibition applies even when such activity is permitted under state law. Prohibition applies even when the activity is purely intrastate and noncommercial. This decision makes clear that federal statutes such as the Controlled Substances Act can override state law. Moreover, federal statutes remain controlling until they are amended or reinterpreted at the federal level.
For cannabis businesses, this distinction has long explained why state legality alone has never been sufficient to secure federal trademark protection. It’s why changes in federal law or federal enforcement policy—rather than state legislation—is decisive for intellectual property rights.
The Cole Memorandum and Why It Never Solved the Cannabis Trademark Problem
In 2013, the Department of Justice issued what became known as the Cole Memorandum, which outlined federal enforcement priorities with respect to marijuana-related activity in states that had legalized cannabis. The memorandum signaled that, under certain circumstances, federal prosecutors should generally refrain from enforcing federal marijuana laws against state-compliant cannabis businesses.
While the Cole Memorandum provided a measure of practical reassurance to operators, it did not change federal law. It was an internal enforcement guidance document, not a statute or regulation. It expressly stated that it did not create any substantive rights or alter the Controlled Substances Act. The memorandum was later rescinded, further underscoring its limited legal status.
For trademark purposes, the Cole Memorandum was largely irrelevant. The USPTO does not base trademark eligibility on enforcement discretion or prosecutorial priorities. Instead, it looks to whether the applicant’s use of the mark is lawful under federal statute. Because the Controlled Substances Act continued to prohibit marijuana as a Schedule I substance, the USPTO consistently refused cannabis trademark applications even during the period when the Cole Memorandum was in effect.
This distinction is critical. The absence of enforcement is not the same as lawful use in commerce. The USPTO has repeatedly made clear that it does not rely on DOJ enforcement guidance when assessing trademark registrability.
Why Cannabis Rescheduling Is Different
Rescheduling cannabis to Schedule III is fundamentally different. Unlike the Cole Memorandum, rescheduling alters the statutory framework itself. Schedule III substances are recognized as having accepted medical use. They may be manufactured and distributed within federally regulated systems.
For trademark analysis, this change is significant. It directly affects whether cannabis-related goods and services are considered lawful under federal law. While rescheduling does not automatically legalize all cannabis commerce, it removes the categorical statutory barrier that previously made lawful use impossible for marijuana products.
The Cole Memorandum left federal illegality intact. Rescheduling modifies the legal foundation on which trademark eligibility is evaluated.
The Role of the Attorney General and the Department of Justice
Implementation of the new scheduling framework will likely depend on guidance issued by the Attorney General through the Department of Justice. The DOJ is responsible for interpreting and enforcing the Controlled Substances Act. It will likely issue guidance clarifying how federal law should be applied under Schedule III.
Such guidance may (emphasis added) address permissible commercial conduct, regulatory oversight, and enforcement priorities. These interpretations will influence agency policies as well. Federal agencies rely on federal legality when applying their own rules.
For trademark purposes, DOJ guidance matters. The USPTO evaluates lawful use by reference to federal law as interpreted and enforced by the executive branch. Although the USPTO does not follow enforcement discretion, it does rely on statutory legality and authoritative agency interpretations when determining whether goods or services may lawfully enter commerce.
What This Change Does — and Does Not — Accomplish
Rescheduling cannabis to Schedule III does not legalize recreational marijuana nationwide. Moreover, rescheduling cannabis does not eliminate all federal restrictions on cannabis commerce. Questions involving interstate commerce, FDA oversight, and regulatory compliance remain unresolved and will likely evolve over time.
What this change does accomplish is the removal of a long-standing statutory obstacle that prevented cannabis brands from even entering the federal trademark system. For the first time, cannabis businesses may have a plausible legal basis to seek federal trademark protection for core products and services. Cannabis businesses will no longer have to rely solely on state registrations or indirect branding strategies.
Special Considerations for Nevada Cannabis Businesses
Cannabis has been legal for recreational use in Nevada since 2017. Our state has developed one of the most visible cannabis markets in the country. Las Vegas, in particular, presents a unique branding environment, where tourism and national exposure have allowed Nevada cannabis brands to gain recognition far beyond state borders.
Such exposure has carried risk. Nevada businesses have built recognizable brands without access to federal trademark protection. This has left them vulnerable to conflicting marks or imitation in other jurisdictions. If federal trademark pathways begin to open, established Nevada operators may be especially well positioned due to documented use, consumer recognition, and accumulated goodwill.
At the same time, increased visibility underscores the importance of ensuring that branding is distinctive, defensible, and aligned with evolving federal requirements.
Preparing for a Shifting Trademark Landscape
Federal trademark rights in the United States are largely priority-based. As the legal framework changes, early strategic decisions may carry lasting consequences. Businesses that delay planning until every regulatory question is resolved may find themselves at a disadvantage once filing pathways become clearer.
This is a good time for cannabis businesses to evaluate their brand portfolios. Cannabis businesses need to assess potential conflicts, and consider how federal trademark protection may fit into their long-term growth and enforcement strategies.
A Developing Story
Rescheduling cannabis represents a meaningful turning point. But today’s news is not the final word. How the Department of Justice implements the change, and how the USPTO responds in its trademark examination practice, will continue to evolve through guidance, agency action, and potential litigation.
This remains a developing story. Cannabis businesses should be prepared to adjust their intellectual property strategies as events unfold. Additional guidance will likely emerge from the Attorney General, the Department of Justice, and other federal agencies. Those who monitor developments closely and adapt deliberately will be best positioned to protect and strengthen their brands in this changing legal environment.